Vascular Endothelial Growth Factor C

A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR D in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.

Also Known As:

Networked: 1257 relevant articles (45 outcomes, 321 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Alitalo, Kari: 54 articles (06/2015 - 01/2002)
2.	Detmar, Michael: 17 articles (02/2015 - 10/2006)
3.	Ylä-Herttuala, Seppo: 12 articles (07/2015 - 09/2002)
4.	Tammela, Tuomas: 12 articles (06/2015 - 09/2002)
5.	Pytowski, Bronislaw: 10 articles (03/2014 - 01/2005)
6.	Stacker, Steven A: 10 articles (08/2013 - 09/2003)
7.	Achen, Marc G: 10 articles (08/2013 - 09/2003)
8.	Alitalo, K: 10 articles (10/2001 - 07/2000)
9.	Kitadai, Yasuhiko: 9 articles (12/2015 - 01/2002)
10.	Jackson, David G: 9 articles (04/2009 - 03/2002)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 11/01/2006 - "Examination of VEGF-C expression in biopsy specimens might be beneficial in predicting pelvic lymph node metastasis." 07/06/2001 - "Furthermore, examination of VEGF-C expression in biopsy specimens may be beneficial in the prediction of pelvic lymph node metastasis." 12/01/2011 - "These results indicate that VEGF-C plays a critical role in lymph node metastasis, in addition to serving as a platform to test the efficacy of various therapeutic modalities against lymph node metastasis." 10/01/2013 - "Therefore, the aim of this study was to investigate whether COX-2 immunohistochemical expression in OSCC was associated with VEGF-C expression, histopathologic parameters, and lymph node metastasis. " 04/01/2008 - "The aim of this study was to evaluate VEGF-C expression as a predictor of occult lymph-node metastasis in OSCC. "
2.	Lymphedema (Milroy Disease) 01/01/2013 - "These results suggested that VEGF-C and ESWT had a synergistic effect and were very effective in alleviating the symptoms of lymphedema and promoting lymphangiogenesis." 05/01/2008 - "Compared with control group, overexpression of VEGF-C enhanced lymphangiogenesis in vivo and mouse tail skin suffering chronic obstructive lymphedema was improved by VEGF-C gene significantly. " 07/01/2015 - "As a precursor to future clinical trials, the therapeutic efficacy and blood vascular side effects of VEGF-C and VEGF-C156S were compared in a large animal model of secondary lymphedema. " 07/01/2011 - "Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema." 03/01/2008 - "VEGF-C protein improved lymphedema at 15 days [reducing dermal thickness from 742 +/- 105 to 559 +/- 141 microm with 95% confidence intervals (CIs), P < 0.05] without increasing lymphatic capillary coverage (11.6 +/- 6.4% following VEGF-C treatment relative to 9.6 +/- 6.2% with 95% CIs, P > 0.50). "
3.	Neoplasms (Cancer) 01/01/2009 - "The size of orthotopic and subcutaneous PC-3/VEGF-C tumors was significantly greater than that of PC-3/mock tumors (both p < 0.001). " 06/01/2014 - "In this study, we investigated the role of Gal-3 in VEGF-C-induced cervical cancer cell invasion. " 01/01/2012 - "This study suggests that tumor-derived VEGF-C/D induce peritumoral lymphangiogenesis, which may be one mechanism that leads to lymphatic invasion and metastatic spread. " 09/01/2011 - "In this study, we measured the COX-2 and VEGF-C expressions by immunohistochemistry in 23 LNM-positive and 20 LNM-negative cervical cancer specimens. " 04/01/2010 - "In the present study, we have investigated the contribution of VEGF-C to tumor cell growth and motility. "
4.	Endometrial Neoplasms (Endometrial Cancer) 01/01/2013 - "VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis." 12/01/2011 - "To evaluate the role of VEGF-C in lymph node metastasis, we developed an animal model by using an endometrial cancer cell line, HEC1A. " 09/01/2005 - "(c) VEGF-C levels in serum and tissue were elevated in cervical cancers especially in advanced grades, while they were normal in serum and tissue from the controls and women with ovarian and endometrial cancers. " 09/01/2005 - "Serum VEGF-C levels, on the other hand, were the highest in late and persistent cervical cancers, but not in ovarian or endometrial cancers. " 03/01/2011 - "Serum levels of VEGF and VEGF-C in patients with endometrial cancer."
5.	Carcinoma (Carcinomatosis) 01/01/2011 - "In this study, we analyzed inhibitory action of a VEGF-C antisense oligoxydeonucleotide (ASODN) on a lung carcinoma cell line A-549 and its invasive ability in vitro. " 06/01/2007 - "The aim of this study was to determine the clinical significance of VEGF-C expression for identifying lymphangiogenesis as a predictor of the local recurrence of rectal carcinoma. " 09/01/2006 - "An immunohistochemical study was applied to 123 specimens of bladder urothelial carcinoma (BUC) to detect VEGF-C and investigate its clinicopathological and prognostic value. " 09/01/2004 - "In this study, we examined the expression of VEGF-C and -D in esophageal carcinoma. " 03/01/2004 - "Accordingly, this study attempted to analyze the association between the Her-2/NEU oncogene and VEGF-C in ovarian carcinoma and to elucidate the molecular mechanism of VEGF-C induction by Her-2/NEU. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor C
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Vascular Endothelial Growth Factor D
4.	Messenger RNA (mRNA)
5.	Small Interfering RNA (siRNA)
6.	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
7.	Vascular Endothelial Growth Factor B
8.	Adenocarcinoma of lung
9.	Hydrogel
10.	Gelatin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplantation (Transplant Recipients)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Therapeutics
5.	Esophagectomy